Up­dat­ed: Roche, Io­n­is launch new Hunt­ing­ton’s dis­ease study

SAN FRAN­CIS­CO — A new study for the Hunt­ing­ton’s dis­ease drug tomin­ersen, de­vel­oped in tan­dem by Roche and Io­n­is, “is open and has start­ed screen­ing el­i­gi­ble pa­tients,” a Roche spokesper­son told End­points News on Wednes­day. The Phase II tri­al will ex­am­ine whether tomin­ersen can slow the pro­gres­sion of Hunt­ing­ton’s in pa­tients aged 25 to 50 with very ear­ly or sub­tle signs of the dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER